Thermo Fisher Scientific

We’re proud to announce the launch of the Centre for Advanced Training and Innovative Research (CATIR) in Pretoria, South Africa, where we will support and train the next generation of African scientists. In partnership with South African Medical Research Council and the Department of Science, Technology and Innovation, CATIR will provide a holistic and hands-on approach to lab training using world class technology for local students. The dedicated facility is also designed to support future pandemic preparedness and local healthcare capacity.

We have expanded our long-standing partnership with Sanofi to acquire Sanofi’s steriles manufacturing site in Ridgefield, New Jersey. Under the agreement, we will continue to manufacture a portfolio of therapies for Sanofi and expand use of the site to meet the growing demand from pharma and biotech customers for U.S. manufacturing capacity. The Ridgefield site is a state-of-the-art sterile fill/finish and packaging facility with a world-class team of more than 200 employees who will join Thermo Fisher following the completion of the transaction. “Sanofi’s Ridgefield site will strengthen our U.S. manufacturing capabilities, enabling us to better support our pharmaceutical and biotech customers with the critical production capacity needed for essential medicines,” said Marc N. Casper, chairman, president and chief executive officer of Thermo Fisher. “We will also expand and further strengthen our long-standing partnership with Sanofi, while investing to bring additional capacity and enhanced capabilities at this site. We look forward to welcoming all Ridgefield employees to Thermo Fisher later this year.”

"The technological innovations in next-generation sequencing (NGS) have truly helped usher the era of personalized medicine," says Thermo Fisher’s Kathy Davy. As a leader in pharma and clinical diagnostics for nearly 30 years, Davy brings her expertise in molecular diagnostics, NGS and clinical genomics to help advance precision oncology by bridging the gap between research and practice. Explore her perspectives on: 🚀 The evolution of NGS technology, enabling faster and more accurate diagnosis. 💡 Overcoming barriers, such as reimbursement coverage and physician education, to integrate NGS into precision oncology. 🤝 The importance of collaboration between pharmaceutical companies and academic institutions to advance cancer diagnostics. 🔍 The transformative impact of AI and machine learning to enhance diagnostic accuracy and patient outcomes. 🌐 Thermo Fisher's role in delivering advanced DNA sequencing technology to help match patients with optimal therapies and forge partnerships around the world to develop new therapies.

Did you know that powerful electron microscopes help scientists develop better treatments for diseases? Cryo-electron microscopy (cryo-EM) allows scientists to capture detailed images of cells, tissues and proteins, enabling them to build realistic 3D models to understand diseases mechanisms and design effective therapies. We support this crucial research with advanced instruments and technologies. Swipe through to learn from Thermo Fisher’s Steve Reyntjens how cryo-EM accelerates scientific innovation and advances drug discovery.

AI in Action: Innovation, Compliance & Real Business Value Our Chief Information Officer, Ryan Snyder, recently joined a panel to delve into one of today's most crucial discussions: responsibly harnessing AI to drive real impact. Insights from the conversation included: 🔹 The shift from centralized to democratized AI 🔹 The role of champions in accelerating adoption 🔹 The importance of roles—not just tools—in shaping innovation 🔹 The need for clear and early communication of AI guardrails 🔹 Meaningful tracking of productivity gains 🔹 The blurring lines between technology and business The key takeaway? AI is now everyone's business, and success hinges on alignment, empowerment, and thoughtful execution. At Thermo Fisher, we are committed to embedding AI thoughtfully across our products, services, and customer interactions. How do you see AI transforming the landscape for science? We’d love to hear your thoughts! Metis Strategy Peter High

Thermo Fisher has been named to the Fortune 500 list of largest companies in the U.S. Thank you to our more than 120,000 colleagues who work every day to enable our customers to make the world healthier, cleaner and safer. Together, we’re advancing science to build a brighter future for all.

For patients facing a diagnosis, every moment matters. New research shows that integrated services can reduce the time drug candidates spend in clinical trials by up to 34 months. This reduction addresses critical bottlenecks and showcases the efficiency of combining contract research and manufacturing services, finds the study from the Tufts Center for the Study of Drug Development. Thermo Fisher's Dr. Daniel Burch emphasizes that savings stem from minimizing idle times between trial phases in Genetic Engineering & Biotechnology News. This is critically important to get treatments to patients faster.

The FDA has approved our Oncomine Dx Express Test on the Ion Torrent Genexus Dx Integrated Sequencer as a companion diagnostic for Dizal’s ZEGFROVY and for tumor profiling. This milestone brings next-generation sequencing closer to where patients receive care, helping to ensure they receive the right therapy, right away. With the ability to deliver critical genomic insights in as little as 24 hours, this innovation helps empower clinicians with the information they need to guide more timely, personalized cancer treatment decisions. The automated workflow of the Genexus Dx System expands access to testing in more clinical settings and helps reduce delays that can stand between patients and the therapies they need. See the full announcement in the comments below.

From stronger, lighter steels for safer transportation to improved battery performance for sustainable energy, advanced imaging and analytical techniques, like transmission electron microscopy, are helping to drive groundbreaking discoveries across industries. Thermo Fisher’s David Wall highlights the evolution of electron microscopy, emphasizing how modern integrated systems provide unparalleled insights that allow even non-experts to achieve high-quality data. This accessibility fuels advancements in quantum computing, catalysis and 2D materials research. Discover how this technology is helping scientists understand our world at the atomic level to pave the way for future advancements: https://lnkd.in/gw5vqXnB

Preserving the Louvre in Paris For decades, we’ve partnered with the Université de Versailles to advance surface analysis innovation, paving the way for groundbreaking discoveries in materials science. A meaningful example of our collaboration is at the Louvre Museum in Paris. The iconic Louvre Pyramid faces corrosion due to environmental wear. With the help of our technology, researchers have developed enhanced surface treatments to protect this architectural marvel. Discover how our technology helps enable the preservation of this iconic structure.